Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION373 in Alexander disease
MOH_2022-01-16_010039Phase 2Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Sep 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alexander disease comparing ION373 with Placebo (2 arms). Primary endpoints: Efficacy, Safety and 2 more. Started Sep 2021; status: recruiting.
02
Drugs
zilganersen
03
Conditions
Alexander disease
Beyond the preview
Go deeper on MOH_2022-01-16_010039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-16_010039.